Arena Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 75   

Articles published

ARNA 4.16 -0.01 (-0.24%)
price chart
4 High-Gross Margin Stocks: Arena Pharmaceuticals, Inc. (ARNA), Gastar ...
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) has return on equity ratio of -54.10%. The company has $881.56 million in market worth.
Related articles »  
Hot Biotech Round Up: Arena Pharmaceuticals, Inc. (NASDAQ:ARNA ...
Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) declared that facts from the stage 3 scientific test program for BELVIQ (lorcaserin HCl) CIV will be launched at the American College of Clinical Pharmacy (ACCP) yearly conference held on last ...
Investor's Alert: Arena Pharmaceuticals, Inc. (ARNA), FuelCell Energy ...  Techsonian (press release)
Related articles »  
Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA ...
Investor-Edge has initiated coverage on the following equities: Arena Pharmaceuticals Inc. (NASDAQ: ARNA), NPS Pharmaceuticals Inc. (NASDAQ: NPSP), XOMA Corporation (NASDAQ: XOMA), Momenta Pharmaceuticals Inc. (NASDAQ: MNTA), and ...
News Review: Merrimack Pharmaceuticals Inc(NASDAQ:MACK), NPS ...  Market News Call
Related articles »  
Pfizer Setback Could Help Arena
Yesterday, big pharma giant Pfizer (NYSE:PFE) received news from the FDA that a panel has taken the stance of recommending that a "black box" warning remain attached to the smoking cessation drug Chantix.
Related articles »  
Pharma Stocks to Watch: Arena Pharmaceuticals, Inc. (NASDAQ:ARNA ...
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Monday said data from phase 3 clinical trials of its obesity drug BELVIQ (lorcaserin HCl) will be presented at the American College of Clinical Pharmacy meeting taking place through Wednesday of this week.
Related articles »  
Belviq Sales Dip: What To Watch For Ahead
Sales of the Arena Pharmaceuticals (NASDAQ:ARNA) anti-obesity pill Belviq seem to be seeing some impacts of seasonality with ups and downs as the Fall weeks progress.
Eisai and Arena Pharmaceuticals Announce Presentation of Lorcaserin HCl ...
WOODCLIFF LAKE, N.J. and SAN DIEGO, Oct. 13, 2014 /PRNewswire/ -- Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that data from the Phase 3 clinical trial program for BELVIQ� (lorcaserin HCl) CIV will be presented at the ...
Related articles »  
Mid Day Alert: Neuralstem, Inc. (NYSEMKT:CUR), Arena Pharmaceuticals, Inc ...
Lakeway, NY - (MARKET NEWS CALL) - 10/20/2014�, an investment community with a special focus on updating investors with recent news on the U.S.
Arena Pharmaceuticals (ARNA) Flagged As Strong On High Volume
Arena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel drugs that target G protein-coupled receptors.
Related articles »  
Belviq Sales Flat - Model Your Expectations (ARNA)
Sales of Arena Pharmaceuticals' (NASDAQ:ARNA) Belviq were essentially flat this week vs. last week, according to industry tracker IMS Health (NYSE:IMS).
Related articles »